Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528148 | 0.76 | CA2 (0.40) | — | |
| SCHEMBL1700474 | 0.69 | — | — | |
| SCHEMBL16500111 | 0.67 | — | — | |
| SCHEMBL7769401 | 0.63 | L3MBTL1 (0.35) | L3MBTL1 | |
| SCHEMBL23142788 | 0.62 | MIF (0.40) | — | |
| SCHEMBL2343950 | 0.60 | — | — | |
| SCHEMBL712181 | 0.60 | ALDH1A1 (0.44) | L3MBTL1 | |
| SCHEMBL7770033 | 0.59 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL5699853 | 0.59 | — | — | |
| SCHEMBL9653080 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0996455-B1 | ALPHA-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | SLOAN KETTERING INST CANCER (US) | 2009-12-16 | — | — | EP | disclosed |
| US-7550146-B2 | Glycopeptide conjugates and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7160856-B2 | α-O-linked glycoconjugates, methods of preparation and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050222398-A1 | Glycopeptide conjugates and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-06 | — | — | US | disclosed |
| EP-0996455-A4 | ALPHA-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | SLOAN KETTERING INSTITUTEFOR C (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1091751-A4 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | SLOAN KETTERING INSTITUTEFOR C (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040102607-A1 | Trimeric antigenic O-linked glycopeptide conjugates, methods of preparation and uses thereof | DANISHEFSKY SAMUEL J (US) | 2004-05-27 | — | — | US | disclosed |
| US-6660714-B1 | Anticancer agents | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | disclosed |
| US-20030083235-A1 | Alpha-o-linked glycoconjugates, methods of preparation and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-01 | — | — | US | disclosed |
| EP-1091751-A1 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2001-04-18 | — | — | EP | disclosed |
| EP-0996455-A1 | $g(a)-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999048515-A9 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | SLOAN KETTERING INST CANCER (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999048515-A1 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1998046246-A1 | α-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222398-A1 | Glycopeptide conjugates and uses thereof | MUC1, FUT5, FUT6 | L3MBTL1 2229/4885 |
| US-20040102607-A1 | Trimeric antigenic O-linked glycopeptide conjugates, methods of preparation and uses thereof | MUC1, OSTC, SIGLEC7 | L3MBTL1 2311/4885 |
| US-20030083235-A1 | Alpha-o-linked glycoconjugates, methods of preparation and uses thereof | MUC1, FUT5, FUT6 | L3MBTL1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.